Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study

Martin van den Bent, B Baumert, SC Erridge, MA Vogelbaum, AK Nowak, M Sanson, AA Brandes, PM Clement, JF Baurain, WP Mason, H Wheeler, OL Chinot, S Gill, M Griffin, DG Brachman, Walter Taal, R Ruda, M Weller, C McBain, J ReijneveldRH Enting, DC Weber, T Lesimple, S Clenton, A van Gijtenbeek, S Pascoe, U Herrlinger, P Hau, F Dhermain, I Heuvel, R Stupp, K Aldape, RB Jenkins, Erik jan Dubbink, Winand Dinjens, P Wesseling, S Nuyens, V Golfinopoulos, T Gorlia, W Wick, J.M. Kros

Research output: Contribution to journalArticleAcademicpeer-review

205 Citations (Scopus)
Original languageUndefined/Unknown
Pages (from-to)1645-1653
Number of pages9
JournalLancet (UK)
Issue number10103
Publication statusPublished - 2017

Cite this